$RGBP No Toxicity Seen in Mice as Regen BioPharma, Inc. Finishes Initial Optimization of its Lead NR2F6 Small Molecule Agonist
Fast Forwarding Checkpoint Medicine
Striving to improve the quality of life by introducing the latest in medical technology for treating cancer and autoimmunity
Regen BioPharma Inc. is a publicly traded biotechnology company (OTCQB: RGBP) and (OTCQB: RGBPP) focused on the immunology and immunotherapy space. The Company plans to rapidly advance novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is advancing small molecule therapies for treating cancer and autoimmune disorders by modulating the Checkpoint NR2F6. The company also developing products treating blood disorders using small molecules and gene silencing (DiffronC), treating cancer with cellular immunotherapy (dCellVax), modulating key molecular processes in cancer stem cell through its patented molecular targeting approaches (BORIS), and repairing damaged bone marrow in patients with aplastic anemia and chemotherapy/radiotherapy treated cancer patients (HemaXellerate).
SAN DIEGO, July 23, 2018 /PRNewswire/ --
Regen BioPharma Inc.'s (RGBP) and (RGBPP) lead candidate drug, RG-NAE005, was tested for its maximum tolerated dose in mice and showed no signs of toxicity. Regen has methodically optimized small molecules that bind to, and activate, the NR2F6 nuclear receptor.
"We are very pleased that we did not see any clinical signs of toxicity at any single dose of RG-NAE005 up to 2,000 mg/kg and did not see any toxicity at repeated doses of 400 mg/kg," says Harry Lander, Ph.D., MBA, President and Chief Scientific Officer of Regen. He also adds, "This is very exciting, as it indicates that the drug will likely be safe in animals as we begin efficacy testing."
The NR2F6 nuclear receptor has been identified as a potentially very important immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator. The NR2F6 program at Regen aims to identify agonists of NR2F6 that should suppress the immune system in diseases where the immune system is over-activated, such as autoimmunity, as well as identifying antagonists in an effort to unleash the cancer-killing potential of a patient's own immune system.
"Drug safety is always the number one concern of any drug development process," says David Koos, Ph.D., Chairman & CEO Regen BioPharma Inc. "We are very pleased to see that this drug is safe in mice. It is another major milestone we have passed with this drug."
About Regen BioPharma Inc.:
Regen BioPharma Inc. is a publicly traded biotechnology company (RGBP) and (RGBPP). The Company is focused on the immunology and immunotherapy space. The Company is focused on rapidly advancing novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is focused on small molecule therapies for treating cancer and autoimmune disorders. Additional information on Regen BioPharma is available at http://www.regenbiopharmainc.com.
Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
CONTACT INFORMATION
Regen BioPharma Inc.
David R. Koos, Ph.D.
Chairman & Chief Executive Officer
+1-619-702-1404 Phone
+1-619-330-2328 Fax
david.koos@regenbiopharma.com
http://www.regenbiopharma.com
https://finance.yahoo.com/news/no-toxicity-se...00274.html
Fast Forwarding Checkpoint Medicine
Striving to improve the quality of life by introducing the latest in medical technology for treating cancer and autoimmunity
Regen BioPharma Inc. is a publicly traded biotechnology company (OTCQB: RGBP) and (OTCQB: RGBPP) focused on the immunology and immunotherapy space. The Company plans to rapidly advance novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is advancing small molecule therapies for treating cancer and autoimmune disorders by modulating the Checkpoint NR2F6. The company also developing products treating blood disorders using small molecules and gene silencing (DiffronC), treating cancer with cellular immunotherapy (dCellVax), modulating key molecular processes in cancer stem cell through its patented molecular targeting approaches (BORIS), and repairing damaged bone marrow in patients with aplastic anemia and chemotherapy/radiotherapy treated cancer patients (HemaXellerate).
SAN DIEGO, July 23, 2018 /PRNewswire/ --
Regen BioPharma Inc.'s (RGBP) and (RGBPP) lead candidate drug, RG-NAE005, was tested for its maximum tolerated dose in mice and showed no signs of toxicity. Regen has methodically optimized small molecules that bind to, and activate, the NR2F6 nuclear receptor.
"We are very pleased that we did not see any clinical signs of toxicity at any single dose of RG-NAE005 up to 2,000 mg/kg and did not see any toxicity at repeated doses of 400 mg/kg," says Harry Lander, Ph.D., MBA, President and Chief Scientific Officer of Regen. He also adds, "This is very exciting, as it indicates that the drug will likely be safe in animals as we begin efficacy testing."
The NR2F6 nuclear receptor has been identified as a potentially very important immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator. The NR2F6 program at Regen aims to identify agonists of NR2F6 that should suppress the immune system in diseases where the immune system is over-activated, such as autoimmunity, as well as identifying antagonists in an effort to unleash the cancer-killing potential of a patient's own immune system.
"Drug safety is always the number one concern of any drug development process," says David Koos, Ph.D., Chairman & CEO Regen BioPharma Inc. "We are very pleased to see that this drug is safe in mice. It is another major milestone we have passed with this drug."
About Regen BioPharma Inc.:
Regen BioPharma Inc. is a publicly traded biotechnology company (RGBP) and (RGBPP). The Company is focused on the immunology and immunotherapy space. The Company is focused on rapidly advancing novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is focused on small molecule therapies for treating cancer and autoimmune disorders. Additional information on Regen BioPharma is available at http://www.regenbiopharmainc.com.
Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
CONTACT INFORMATION
Regen BioPharma Inc.
David R. Koos, Ph.D.
Chairman & Chief Executive Officer
+1-619-702-1404 Phone
+1-619-330-2328 Fax
david.koos@regenbiopharma.com
http://www.regenbiopharma.com
https://finance.yahoo.com/news/no-toxicity-se...00274.html
